![]() Nicolas is a Senior Editorial Board Member of BMC Cancer. She has served on the Boards of Trustees for the Chicago Medical Society and the Illinois State Medical Society and has chaired various advocacy groups through these organizations. ![]() Fidler has authored and co-authored several manuscripts, publications and abstracts. ![]() Fidler is the national principal investigator for the ADURA trial of osimertinib in surgically resected patients with the EGFR activating mutation and the local principal investigator for the ORCHARD trial in the Midwest, which seek to identify the next best treatments for patients with EGFR activating gene mutations that have cancer progression after osimertinib. ![]() She has enrolled patients on several clinical trials testing both immune checkpoint inhibitors and targeted therapies. Her translational research interests focus on mechanisms of chemotherapy and radiotherapy resistance, predictors of response to immune check point inhibitors, and cancer cachexia. Fidler specializes in the treatment of thoracic and head and neck cancers. She received her medical degree from the Albert Einstein College of Medicine in Bronx, New York and then went on to complete her internal medicine residency at the McGaw Medical Center of Northwestern University in Chicago and Fellowship in Hematology/Oncology at Rush University Medical Center. Fidler attended Cornell University in Ithaca, New York for undergraduate work. Fidler is the section chief of medical oncology and associate professor in the Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy at Rush Medical College. He serves as Senior Board Member since August 2020.ĭr. He completed his medicine residency at Good Samaritan hospital, affiliated with Johns Hopkins University in Baltimore in 2010, and medical oncology and hematology fellowship at the University of Texas MD Anderson Cancer Center in 2013.His research interests include the investigation of signaling pathways and biological processes controlled by MSI2 and developing novel therapeutic approaches to target MSI2 in lung cancer. He joined the editorial board of BMC Cancer in 2016 as Deputy Section Editor. He received his PhD in cancer biology and molecular biology at the University of Texas MD Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences in Houston in 2005. Dr Boumber graduated from the Rostov State Medical University, Russia and qualified as MD in 1999. Boumber has previously worked as Assistant Professor in the Thoracic Section of the Department of Hematology/Oncology at the Fox Chase Cancer Center, Philadelphia, USA. Yanis Boumber, MD, PhD, Associate Professor, Division of Hematology/ Oncology, Section of Thoracic Head and Neck Medical Oncology, at Northwestern University Cancer Center in Chicago. Bismar lab is funded by Prostate Cancer Canada, Canadian Cancer Society and the prostate Cancer Foundation of USA with many collaborations nationally and internationally. Bismar aims to develop signatures that infer patients at highest risk for developing NEPCA post hormonal therapy. The second area focuses on advanced castrate resistant and neuroendocrine disease, where Dr. Firstly, in the active surveillance population where developing signatures that could be clinically implemented to develop personalized protocols for follow-up and re-biopsy of such patients. His research focuses on characterizing novel molecular signatures and biomarkers to infer disease progression, targeting two clinical areas. He is also a consultant for genitourinary pathology and oncology cases for various department members. Bismar is a clinician scientist and urological pathologist working as primary pathologist for signing out genitourinary oncology cases. ![]() Dr Bismar joined the BMC Cancer Senior Editorial Board in September 2020 and is currently a Professor at the University of Calgary and Adjunct Professor in the Department of Oncology at McGill University. ![]()
0 Comments
Leave a Reply. |